PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml

• DOI: 10.1038/s41598-024-57337-y
• Publication Date: 2024-03-19T11:02:05Z
• Authors: Jing Wen; Wei Liu; Xiaocui Shen; Wei Hu
• Keywords: Nomogram; Cut-off

Abstract This study intended to evaluate the diagnostic accuracy of prostate imaging reporting and data system (PI-RADS) prostate-specific antigen density (PSAD) for clinically significant cancer (csPCa) with PSA levels 4–10 ng/ml. Between July 2018 June 2022, a total 453 patients ng/ml were retrospectively included, which randomly assigned training group (323 patients) validation (130 patients). Sensitivity, specificity, positive predictive value (PPV), negative (NPV) their 95% CI calculated. The overall performance was determined area under receiver operating characteristic curve (AUC), an integrated nomogram combining PI-RADS score PSAD constructed tested in cohort. In group, AUC 2.1 alone 0.875 (95% 0.834–0.916) 0.712 0.648–0.775). At cutoff ≥ 4, sensitivity specificity 86.2% 77.4–1.9%) 84.7% 79.6–88.8%), respectively. For PSAD, 73.3% 63.0–82.4%) 62.1% 55.8–68.5%) at 0.162 ng/ml/ml. While improved significantly, 0.893 0.853–0.933). yielded 0.871 0.807–0.934), is significantly higher than (0.829, 0.759–0.899, P = 0.02). ng/ml, demonstrated moderate whereas showed high performance. By combination together, could be significantly.